Completed PHASE3 INTERVENTIONAL 2-arm NCT02268045

Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma

A Randomized, Double-blind, Phase III Study Comparing Biosimilar Rituximab (RTXM83) Plus CHOP Chemotherapy Versus a Reference Rituximab Plus CHOP (R-CHOP) in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Given as First Line

Sponsor: Actoverco

Conditions Diffuse Large B-cell Lymphoma

Interventions Mabthera RTXM83

Updated 12 times since 2017 Last updated: Aug 28, 2019 Started: May 31, 2013 Primary completion: May 31, 2016 Completion: Jul 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Diffuse Large B-cell Lymphoma and is currently completed. Actoverco leads this study, which shows 12 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

12 versions recorded

Nov 2025 — Present [monthly]

Completed PHASE3
Sep 2025 — Nov 2025 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Oct 2022 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 7 earlier versions

Jan 2021 — Oct 2022 [monthly]

Completed PHASE3
May 2020 — Jan 2021 [monthly]

Completed PHASE3
Oct 2019 — May 2020 [monthly]

Completed PHASE3
Jun 2018 — Oct 2019 [monthly]

Completed PHASE3
May 2018 — Jun 2018 [monthly]

Completed PHASE3
Oct 2017 — May 2018 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Jan 2017 — Oct 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Actoverco
Innogene Kalbiotech Pte. Ltd
Key Oncologics (Pty) Ltd
Laboratorio Elea Phoenix S.A.
Laboratorios de Productos Éticos C.E.I.S.A.
Libbs Farmacêutica LTDA
Nanolek LLC
Pisa® Farmacéutica
Tecnoquimicas S.A
mAbxience Research S.L.

Data source: mAbxience Research S.L.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arkhangelsk, Russia , Asunción, Paraguay , Bandung, Indonesia , Bangalore, India , Belo Horizonte, Brazil , Bogotá, Colombia , Buenos Aires, Argentina , Cali, Colombia , Campinas, Brazil , Cape Town, South Africa and 54 more locations